InMed Pharmaceuticals Q4 2026 Earnings Results & Report

InMed Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$94.4436
• Beat/Miss: N/A
• One Year Ago EPS: N/A

InMed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.06 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

InMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder. The company has also advanced INM-088, an eye-drop formulation designed for potential use in glaucoma. The development status of these programs may change as clinical and regulatory work progresses.

In addition to its pharmaceutical programs, InMed expanded into the commercial rare-cannabinoid ingredient market through its acquisition of BayMedica. That business develops and supplies rare cannabinoids, including ingredients for pharmaceutical, nutraceutical, health and wellness, and other commercial applications. InMed is headquartered in Vancouver, British Columbia, and its shares trade on Nasdaq under the symbol INM.